BREAST CARCINOMA ANTIGENS F36/22 AND M7/105

乳腺癌抗原 F36/22 和 M7/105

• 批准号: 3172050
• 负责人: Tsann Ming Chu
• 金额: $ 9.79万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-04-01 至 1986-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3172050
• 关键词: affinity chromatography; breast neoplasms; electrofocusing; enzyme linked immunosorbent assay; gene expression; human tissue; immunochemistry; metastasis; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunology; radiotracer; serology /serodiagnosis; tissue /cell culture; tumor antigens

Immunological and biochemical studies will be performed using monoclonal antibodies F36/22 and M7/105 which recognize determinants expressed maximally on breast carcinomas. The in vivo distribution and molecular profile of these antigens will be determined by analysis against a large panel of normal and tumor tissues. Antibodies F36/22 and M7/105 will be employed in immunohistochemical staining studies in order to phenotypically-classify primary and metastatic breast carcinomas. The immunotherapeutic applicability of these antibodies will be examined in vitro against breast carcinoma cell lines and also in vivo using human tumor-bearing athymic mice. Breast carcinoma antigens will be purified by the use of biochemical fractionation procedures which shall include monoclonal antibody-ligand chromatography. Purified antigen will be used to generate immunoassay procedures for serologic analyses in order to obtain baseline data regarding the value of these tests in diagnostic and patient management applications.

将使用单克隆抗体进行免疫学和生物化学研究。 抗体F36/22和M7/105识别表达的决定簇， 对乳腺癌的疗效最大。 体内分布和分子水平 这些抗原的谱将通过针对大的 正常组织和肿瘤组织组。 抗体F36/22和M7/105将在 用于免疫组织化学染色研究， 表型分类原发性和转移性乳腺癌。 的 这些抗体的免疫适用性将在 体外抗乳腺癌细胞系以及体内使用人 荷瘤无胸腺小鼠。 乳腺癌抗原将通过以下方法纯化： 使用生化分离程序，其中应包括 单克隆抗体-配体层析。 将使用纯化抗原 生成用于血清学分析的免疫测定程序， 获得关于这些测试在诊断和治疗中的价值的基线数据， 患者管理应用程序。

项目成果

Reactivity of monoclonal antibody F36/22 with human ovarian adenocarcinomas.

单克隆抗体 F36/22 与人卵巢腺癌的反应性。

• 发表时间: 1984
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Croghan,GA;Wingate,MB;Gamarra,M;Johnson,E;Chu,TM;Allen,H;Valenzuela,L;Tsukada,Y;Papsidero,LD
• 通讯作者: Papsidero,LD

Expression of ductal carcinoma antigen in breast cancer sera as defined using monoclonal antibody F36/22.

使用单克隆抗体 F36/22 定义乳腺癌血清中导管癌抗原的表达。

• 发表时间: 1984
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Papsidero,LD;Nemoto,T;Croghan,GA;Chu,TM
• 通讯作者: Chu,TM

Immunoaffinity isolation of ductal carcinoma antigen using monoclonal antibody F36/22.

使用单克隆抗体 F36/22 免疫亲和分离导管癌抗原。

• DOI: 10.1016/0161-5890(84)90153-6
• 发表时间: 1984
• 期刊: Molecular immunology
• 影响因子: 3.6
• 作者: Papsidero,LD;Croghan,GA;Johnson,EA;Chu,TM
• 通讯作者: Chu,TM

Physicochemical purification and immunological characteristics of ductal carcinoma antigen.

导管癌抗原的理化纯化及免疫学特性。

• DOI: 10.1002/ijc.2910370510
• 发表时间: 1986
• 期刊: International journal of cancer
• 影响因子: 6.4
• 作者: Papsidero,LD;Johnson,EA
• 通讯作者: Johnson,EA